Sterling Capital Management LLC Sells 14,249 Shares of Haleon plc (NYSE:HLN)

Sterling Capital Management LLC trimmed its position in shares of Haleon plc (NYSE:HLN) by 9.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 140,594 shares of the company’s stock after selling 14,249 shares during the quarter. Sterling Capital Management LLC’s holdings in Haleon were worth $1,341,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Argent Trust Co boosted its stake in shares of Haleon by 98.3% during the 4th quarter. Argent Trust Co now owns 29,880 shares of the company’s stock worth $285,000 after purchasing an additional 14,809 shares during the period. Legacy Financial Advisors Inc. boosted its position in shares of Haleon by 13.0% during the fourth quarter. Legacy Financial Advisors Inc. now owns 23,597 shares of the company’s stock valued at $225,000 after buying an additional 2,720 shares during the period. Scotia Capital Inc. grew its stake in shares of Haleon by 567.4% during the fourth quarter. Scotia Capital Inc. now owns 78,563 shares of the company’s stock valued at $750,000 after buying an additional 66,792 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Haleon by 5.9% in the fourth quarter. Bessemer Group Inc. now owns 22,301 shares of the company’s stock worth $212,000 after buying an additional 1,236 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Haleon in the fourth quarter worth approximately $42,193,000. Institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

HLN has been the subject of a number of recent analyst reports. HSBC restated a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Finally, Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Haleon has an average rating of “Hold” and a consensus target price of $10.95.

Haleon Trading Up 0.7 %

NYSE HLN opened at $10.13 on Tuesday. The company’s 50-day simple moving average is $10.05 and its two-hundred day simple moving average is $9.81. Haleon plc has a one year low of $8.03 and a one year high of $10.80. The company has a market capitalization of $45.76 billion, a price-to-earnings ratio of 29.79, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. Equities analysts forecast that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This is an increase from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. Haleon’s payout ratio is currently 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.